Mylan, Novartis settle Hatch-Waxman case on Femara

Details of the settlement are confidential, but Mylan stated it will market a generic version of Femara before the patent expires.

A press release on tradingmarkets stated: Generic drugmaker Mylan said that under the agreement it had a patent licence allowing it to market its Letrozole tablets prior to the expiry of a U.S. patent on Femara.